about
Involvement of Host Non-Coding RNAs in the Pathogenesis of the Influenza VirusPreclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesSeasonal influenza vaccination and technologies.Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine.Altered viral replication and cell responses by inserting microRNA recognition element into PB1 in pandemic influenza A virus (H1N1) 2009.Current and emerging cell culture manufacturing technologies for influenza vaccines.Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.Production of avian influenza virus vaccine using primary cell cultures generated from host organs.Synthetic generation of influenza vaccine viruses for rapid response to pandemics.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.Bacterial ghosts as adjuvants: mechanisms and potential.Fast vaccine design and development based on correlates of protection (COPs).Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsIs rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis.Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.Influenza vaccines: unmet needs and recent developments.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Development of a universal CTL-based vaccine for influenza.Cell-culture derived fowl adenovirus serotype 4 inactivated vaccine provides complete protection for virus infection on SPF chickens.Vaccine approaches conferring cross-protection against influenza viruses.Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.Vaccines 'on demand': science fiction or a future reality.Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method.Establishment and evaluation of the goose embryo epithelial (GEE) cell line as a new model for propagation of avian viruses.
P2860
Q29048649-C19302D1-5118-4766-BC52-4006993E868CQ30352121-95C80AB4-4A86-4B67-8EB2-56696B58DA12Q30360897-6B1B9DD7-8AD0-48D3-993C-A8EDD36732ABQ30363689-2E4196A9-733B-4841-B433-B37833BB8034Q30372845-C6AA4BB0-CFC8-4A3F-8258-637A40C7636CQ30373128-B598B8F1-BA0C-45F5-A323-F4623E1283E6Q30373843-3DFFF4AA-2B84-4195-845A-CB567E1DB176Q30375250-95485B0C-FFE3-474D-84A8-CBAC06A08B51Q30388063-7628D74C-FF08-442A-859C-4AA455A30E6AQ30428538-33F70E58-6C69-4CE1-AF05-E011CF13E95BQ30430578-93FBE7B7-FD6C-4D89-9164-4B5B26782682Q33820732-BC8A3F5E-531A-4E91-A354-B35C21AD4942Q33830398-35EEC66A-ED16-4639-8590-46493291B4ACQ34291098-A61E993F-8889-4977-87D2-226859BC8D3CQ35826747-A933DCA2-68B2-4D07-9D10-BB7FB173F614Q36367842-B71A5236-3F9B-44DF-89EF-DD8EA1A647FEQ37231850-24FA1ECE-2F46-4388-B872-4A75EBDF873BQ37518273-3B41242E-BE9E-4783-946B-051BCA948D9BQ38045920-48912851-2602-4DF3-929A-0D9854231076Q38075677-690AE068-39A5-4290-A804-CAD3D2339205Q40097049-41F9664D-5397-47F5-B03D-596DDB5B2E11Q41934895-BC6CC2CD-B607-464E-9FDA-CBAE27A85FFCQ41942589-A50686AA-77D9-43E9-9620-1D22201B8B2BQ44095960-266B9A0B-2C80-429E-9186-2C71D879171FQ47602225-E72A1430-99D9-4A44-A770-872230A20B14Q52679486-F2EE3A3A-E550-40C0-8083-30480745B88E
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
New technologies for influenza vaccines.
@ast
New technologies for influenza vaccines.
@en
type
label
New technologies for influenza vaccines.
@ast
New technologies for influenza vaccines.
@en
prefLabel
New technologies for influenza vaccines.
@ast
New technologies for influenza vaccines.
@en
P2093
P2860
P356
P1476
New technologies for influenza vaccines.
@en
P2093
Giuseppe Del Giudice
Philip R Dormitzer
Theodore F Tsai
P2860
P356
10.4161/HV.8.1.18859
P577
2012-01-01T00:00:00Z